BAYLOR GENETICS
Company Snapshot
Company Overview
Baylor Genetics is developing and commercializing clinical genetic diagnostic services. The joint venture company comprises the sequencing and analysis technologies from Baylor College of Medicine and the commercial diagnostics abilities from Miraca.
The founding of Baylor Genetics provided the corporate vehicle for commercializing Baylor’s pioneering work in sequencing DNA and mapping genetic networks.
Baylor Genetics specializes in sequencing-based clinical genetic testing and has a broad test menu with more than 4,000 available. Platforms include NGS, cytogenetics and chromosomal microarray.
In January 2017, Baylor Genetics began marketing PreSeek, a prenatal multigene sequencing screening diagnostic. The test sequences cell-free fetal DNA for de novo disease-causing variants correlated with single-gene conditions occurring in cardiac, neurological and skeletal systems.
In November 2020, Baylor Genetics formed an alliance with Aspira Women’s Health to co-develop an early detection test for ovarian cancer. Aspira will bring its experience in recruitment of patient samples and assay development to this collaboration.
BAYLOR GENETICS In News
Company's Business Segments
- Genetic Testing : This segment includes Whole Exome Sequencing, Whole Genome Sequencing, Chromosomal Microarray Analysis, Global Metabolomic Assisted Pathway Screen, Mitochondrial Testing.
Applications/End User Industries
- Oncology
- Biochemical
- Clinics
- Genetic Testing
- Healthcare
- SNP Analysis
- Enzyme Assays
- Bioinformatics Technology
- Cancer Mutation
- Cancer Microarrays
